美罗培南与亚胺培南治疗重度肺部感染疗效及安全性分析

Analysis the efficacy and safety of meropenem and imipenem in treatment of severe pulmonary infection

目的对比分析美罗培南与亚胺培南对重度肺部感染患者的疗效及安全性。方法 2015年1-12月按照随机数字表法将我院收治的90例重度肺部感染患者分为两组,即对照组和实验组,各45例,前者应用亚胺培南,后者应用美罗培南;对比两组细菌学疗效、临床疗效、不良反应发生率、成本-效果情况及住院时间。结果 1个疗程后,实验组细菌学总有效率为100.00%,显著高于对照组91.11%（P〈0.05）。实验组临床总有效率为95.56%,显著高于对照组82.22%（P〈0.05）。实验组不良反应发生率为2.22%,略低于对照组4.44%（P〉0.05）。实验组成本效果比为4453.7,优于对照组6930.2。实验组住院时间略短于对照组（P〉0.05）。结论采用美罗培南治疗重度肺部感染不仅细菌学疗效及临床疗效好,而且安全性及经济性佳,值得推广及应用。

Objective To analyze the efficacy and safety of meropenem and imipenem in treatment of severe pulmonary infection. Methods 90 cases with severe pilmonary infection from Jan 2015 to Dec 2015 were selected, and were divided into experimental group（47 cases） and control group（47 cases） according to the random number table method. Control group was treated with imipenem, and study group was treated with meropenem. Occurrence of bacteriologic effect, clinical curative effect, adverse reaction rate, cost effectiveness and hospitalization of two groups were compared. Results After a course of treatment, occurrence of bacteriologic effect of experimental group was 95.56%, which was higher than that of control group（82.22%）（P〈0.05）. Adverse reaction rate of experimental group was 2.22%, which was lower than that of control group, but no significant difference（4.44%）（P〉0.05）. Cost effectiveness ratio of experimental group were 4453.7, which was better than control group（6930.2）. Length of stay of experimental group was shorter than that of control group, but no significant difference（P〉0.05）. Conclusion Meropenem in treatment of severe pulmonary infection shows good clinical efficacy and bacteriological efficacy, with good security and economy, worthy of clinical promotion.